CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Supplementary Table. Effectiveness of 2023–2024 Monovalent COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection Compared to Receipt of Bivalent Vaccination or Receipt of No Vaccination or Original Monovalent Vaccination Only, by Age Group and Interval Since Last Dose — Increasing Community Access to Testing Program, United States, September 2023–January 2024
-
02/01/2024
-
Source: MMWR: Morbidity and Mortality Weekly Report 2024; v. 73, no. 4
Details:
-
Alternative Title:Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributableto Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024: Supplementary Table. Effectiveness of 2023–2024 Monovalent COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection Compared to Receipt of Bivalent Vaccination or Receipt of No Vaccination or Original Monovalent Vaccination Only, by Age Group and Interval Since Last Dose — Increasing Community Access to Testing Program, United States, September 2023–January 2024
-
Corporate Authors:
-
Source:
-
Series:
-
ISSN:0149-2195 (print);1545-861X (digital);
-
Document Type:
-
Place as Subject:
-
Pages in Document:1 pdf page
-
Volume:73
-
Issue:4
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-138.40 KB]